Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
32 /100
COMPONENT-LIMITED
Score updated Oct 27, 2026

RANI — Rani Therapeutics Holdings, Inc. Dilution Risk Tracker

Track RANI dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track RANI — Get alerts when the score changes →

As of October 27, 2026, Rani Therapeutics Holdings, Inc. (RANI) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Rani Therapeutics Holdings, Inc. has a market capitalization of $85.03M, 139.40M shares outstanding, 75 institutional holders tracked. Stored dilution-related fields include 6.58M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
52
💰 Cash Runway
10
📊Float Risk—
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
model est. 27%
🔄 Reverse Split model est. 55%
• 50-day avg $0.95 below $1 exchange minimum
🔔 Track RANI — Get forecast alerts →

Market Data

Market Cap$85.03M
Shares Outstanding139.40M
FloatN/A
Cash$103.37M
Debt$3.94M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore32/100DilutionWatch score record
Shares Outstanding139.40MVerified float table or market cache
Public FloatNot availableVerified float table or market cache
Market Cap$85.03MMarket data cache
Cash Runway34.3 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding Warrants6.58MSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 3 1, 4 3, SC 13G/A 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

RANI SEC Filing Activity — Last 12 Months

Shares outstanding reported by RANI on the cover page of its latest 10-K/10-Q: 139.40M as of July 31, 2026.

DilutionWatch recorded no shelf, registration or prospectus documents for RANI in the last 12 months. Full filing list on SEC EDGAR →

FormWhat it isFilingsMost recent
8-Kcurrent report (material event)1Aug 04, 2026
DEF 14Aproxy statement1Apr 16, 2026
SC 13G/Aamended passive >5% holder filing1Aug 14, 2026
3initial insider ownership6Aug 04, 2026
5annual insider ownership20Sep 29, 2026

Institutional Holdings

QoQ: ↑ 1.3% shares (2026Q1 vs prior)
75 institutional holders · 49.36M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 9.25M shares
#2 RA CAPITAL MANAGEMENT, L.P. 8.50M shares
#3 SAMSARA BIOCAPITAL, LLC 8.50M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest8.16M
Days to Cover14.2
% of FloatN/A
FINRA data as of Oct 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-26
xbrl XBRL CONVERTIBLE 2022-03-31
4 INSIDER TRANSACTION 2026-09-29
4 INSIDER TRANSACTION 2026-09-29
SC 13G/A BENEFICIAL OWNERSHIP 2026-08-14
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual RANI Dilution Snapshot

Rani Therapeutics Holdings, Inc. (RANI) has a DilutionScore of 32/100, rated Medium dilution risk. Score date: October 27, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

RANI's DilutionScore is currently 32/100 (Medium risk), with 6 score changes tracked over 89 days. The score deteriorated from 40/100 (Medium risk).

Period Score Risk Level Duration
Oct 22 – Oct 27, 202632/100MEDIUM6 days
Oct 21, 202640/100MEDIUM1 day
Oct 11 – Oct 20, 202650/100MEDIUM10 days
Sep 28 – Oct 10, 202638/100MEDIUM13 days
Aug 22 – Sep 27, 202634/100MEDIUM37 days
Aug 14 – Aug 21, 202638/100MEDIUM7 days
Jul 30 – Aug 13, 202634/100MEDIUM15 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

RANI shares outstanding have increased 0.1% from 99.72M (Mar 2026) to 99.81M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 17, 202699.81M70.78M▲ 0.19%
May 15, 202699.81M70.65M▲ 9.78%
Apr 26, 202699.81M64.35M▲ 0.05%
Apr 01, 202699.72M64.32M▲ 1.24%
Mar 30, 202699.72M63.53M▼ 0.02%
Mar 28, 202699.72M63.54M▲ 2.24%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track RANI Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment RANI files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking RANI — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,566+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for RANI
RANI FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.